Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NEW YORK, June 8, 2015 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) ("Caladrius" or the "Company"), a cell therapy leader with a late-stage clinical program for immuno-oncology, today...
-
NEW YORK, June 4, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) (to be renamed Caladrius Biosciences, Inc. as of June 8, 2015), a cell therapy leader with a late-stage clinical program for...
-
NEW YORK, June 2, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company", to be renamed Caladrius Biosciences, Inc. as of June 8, 2015), announced today the closing of a...
-
NEW YORK, May 29, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a biopharmaceutical company developing novel cell-based individualized medicine therapies, today...
-
NEW YORK, May 27, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), announced today the pricing of an underwritten public offering of 12,500,000 shares of common stock...
-
NEW YORK, May 27, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), announced today that it is commencing an underwritten public offering of its common stock. The...
-
NEW YORK, May 26, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a biopharmaceutical company developing novel, cell-based individualized medicine therapies, today...
-
NEW YORK, May 21, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) announced Thursday that it will receive one of the largest research grants of its kind to support its pioneering treatment for...
-
NEW YORK, May 5, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a biopharmaceutical company developing novel, cell-based individualized medicine therapies, announced...
-
NEW YORK, May 4, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell-based individualized medicine therapies, announced today that the Company's...